Half life of the Pfizer vaccine in the human body
Erika Whittome made this Official Information request to University of Auckland
The request was refused by University of Auckland.
From: Erika Whittome
Dear University of Auckland,
This request is to Ms Petoussis Harris under your employ who recently gave evidence at the royal Covid enquiry last week. She said that the vaccine and its associated manufactured spike proteins break down in a couple of days in the human body.
This information request is to her:
I note that the product Comirnaty which Medsafe approved has the following description on its data sheet:
"The active ingredient is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ".
1. Is the messenger ribonucleic acid or mRNA a genetic material?
2. What is the excretion and half-life of this active ingredient?
3. When does the messenger ribonucleic acid cease to give instructions to DNA in the human recipient?
Yours faithfully,
Erika Whittome
From: Erika Whittome
Dear University of Auckland & Ms Petoussis-Harris,
COVID-19 mRNA and adenoviral vector products function by delivering genetic instructions to human cells, which then produce foreign proteins (like the SARS-CoV-2 spike protein). This mechanism directly aligns with the FDA's own definitions of "gene therapy products."
The FDA has established the regulatory definition of gene therapy products through its authoritative guidance documents, specifically: "Guidance for Human Somatic Cell Therapy and Gene Therapy" (1998), which states that
"Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use," and "Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications" (2020), which defines gene therapy products as those that "mediate their effects by transcription and/or translation of transferred genetic material and/or by integrating into the host genome." These guidance documents are binding on the FDA under the Accardi doctrine, United States ex rel. Accardi v. Shaughnessy, 347 U.S. 260 (1954), which prohibits agencies from departing from their own established rules, procedures, or interpretive frameworks without adequate justification.
See United States ex rel. Accardi v. Shaughnessy, 347 U.S. 260 (1954).
(From
https://www.regulations.gov/document/FDA...)
Yours faithfully,
Erika Whittome
From: Landon Watt
University of Auckland
Dear Erika,
I refer to your request of 17 July 2025. The University’s response
follows.
The Official Information Act 1982 (“OIA”) allows eligible requesters to
make requests for specified official information held by entities subject
to the OIA. Your request is for official information held by the
University rather than a specific staff member. You requested the same
information from the Ministry of Health on 17 January 2025 (as published
on fyi.org.nz at [1]Genetic content of Comirnaty and its half life - a
Official Information Act request to Ministry of Health - FYI) and received
their response. We believe that the information requested is more closely
connected with the functions of the Ministry of Health. In these
circumstances, we are required by section 14 of the OIA to transfer your
request. You will hear further from the Ministry of Health concerning that
part of your request.
You have the right to make a complaint to an Ombudsman if you are
dissatisfied with this response.
Yours sincerely,
Landon Watt
Legal Advisor
Office of the Vice-Chancellor
Waipapa Taumata Rau | University of Auckland
show quoted sections
From: OIA Requests
Kia ora Erika,
The Ministry has received a transfer of the below request from the
University of Auckland:
“I note that the product Comirnaty which Medsafe approved has the
following description on its data sheet:
"The active ingredient is a single-stranded, 5’-capped messenger RNA
(mRNA) produced using a cell-free in vitro transcription from the
corresponding DNA templates, encoding the viral spike (S) protein of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ".
1. Is the messenger ribonucleic acid or mRNA a genetic material?
2. What is the excretion and half-life of this active ingredient?
3. When does the messenger ribonucleic acid cease to give instructions to
DNA in the human recipient?”
The Ministry notes we have answered your query in January 2025:
[1]https://fyi.org.nz/request/29775-genetic...
as such we refer you to that response.
Under section 28(3) of the Act, you have the right to ask the Ombudsman to
review the Ministry’s decision to transfer your request. The Ombudsman may
be contacted by email at: [2][email address] or by calling
0800 802 602.
Ngâ mihi
OIA Services Team
Ministry of Health | Manatû Hauora
M[3]inistry of Health information releases
show quoted sections
References
Visible links
1. https://fyi.org.nz/request/29775-genetic...
2. mailto:[email address]
mailto:[email address]
3. https://www.health.govt.nz/about-ministr...
https://www.health.govt.nz/about-ministr...
From: Erika Whittome
Dear OIA Requests,
Information was provided by a staff member at the University of Auckland at the Royal Covid enquiry . I ask that the University supply the requested information given the UoA staff member attended the inquiry in person speaking based on her standing at the U of A, not based on her standing at the MoH .
Yours sincerely,
Erika Whittome
From: Erika Whittome
Dear OIA Requests,
I have lodged a complaint with the ombudsman
Yours sincerely,
Erika Whittome
From: OIA Requests
Kia ora Erika,
Thank you for your email. The Ministry of Health stands by its decision
and has nothing further to add.
Under section 28(3) of the Act, you have the right to ask the Ombudsman to
review any decisions made under your requests. The Ombudsman may be
contacted by email at: [1][email address] or by calling 0800
802 602.
Ngā mihi
OIA Services Team
Ministry of Health | Manatū Hauora
M[2]inistry of Health information releases
show quoted sections
Please use this email address for all replies to this request:
[FOI #31634 email]
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[8]https://aus01.safelinks.protection.outlo...
If you find this service useful as an Official Information officer, please
ask your web manager to link to us from your organisation's OIA or LGOIMA
page.
-------------------------------------------------------------------
show quoted sections
References
Visible links
1. mailto:[email address]
2. https://www.health.govt.nz/about-ministr...
3. https://fyi.org.nz/request/29775-genetic...
4. mailto:[email
5. mailto:[email
6. https://www.health.govt.nz/about-ministr...
7. https://www.health.govt.nz/about-ministr...
8. https://fyi.org.nz/help/officers
Things to do with this request
- Add an annotation (to help the requester or others)
- Download a zip file of all correspondence (note: this contains the same information already available above).
Offensive? Unsuitable?
Requests for personal information and vexatious requests are not considered valid requests for Official Information (read more).
If you believe this request is not suitable, you can report it for attention by the site administrators
Report this requestAct on what you've learnt
Similar requests
Request for communications between Chris Hipkins and the Medical Council of NZ relating to Covid19 2020-21
To Chris Hipkins by Robin Benson
Request for information on post-vaccination production of spike proteins.
To Ministry of Health by R Bailey
Evidence, research, data or any material considered in arriving at Covid-19 vaccine mandate policy
To Auckland Council by Robin Benson
SPENCER JONES left an annotation ()
International Journal of Vaccine Theory, Practice, and Research 4(1)
https://doi.org/10.56098/hqjnk479
From Innovation to Inquiry — COVID -19 mRNA
Vaccination and Its Global Consequences —
with Special Reference to New Zealand
Bruce Rapley, PhD
Consultant and Independent Researcher, Smart Technology, New Zealand;
Abstract
The COVID-19 pandemic involved the rapid deployment of novel biomedical technologies. Chief
among them were synthetic RNAs, introduced with limited longitudinal data, yet supported by
institutional consensus, and expedited regulatory pathways. Subsequent developments revealed
questions regarding safety, ethics, efficacy, and governance. This formal review, with specific
reference to New Zealand, examines the COVID-19 response, using synthetic RNA distributed
under Emergency Use Authorizations. A range of post-deployment signals, including immunological
anomalies (IgG4 class switching), clotting disorders, and residual DNA elements, remain
insufficiently investigated. Regulatory responses have not met the standard of precaution typically
applied to novel gene therapies. At the same time, low-cost interventions such as ivermectin were de-
prioritized, or suppressed. The temporal association between vaccine rollouts and excess non-
COVID mortality in several high-uptake nations warrants systematic, transparent analysis. To date,
no national authority has published comprehensive disaggregated mortality data by vaccination
status.
Keywords: adverse events, COVID-19 vaccination, Emergency Use Authorization, EUA, genetic engineering, IgG4 class
switching, mRNA vaccination, plasmid DNA, post-market surveillance, therapeutic suppression, ivermectin, spike protein toxicity,
regulatory oversight failure, scientific censorship, turbo cancer, vaccine-induced thrombotic thrombocytopenia, VITT
Link to this